KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Research & Development (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Research & Development for 18 consecutive years, with $1.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Research & Development rose 16.28% year-over-year to $1.5 billion; the TTM value through Mar 2026 reached $6.1 billion, up 16.41%, while the annual FY2025 figure was $5.9 billion, 13.99% up from the prior year.
  • Research & Development hit $1.5 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $1.6 billion in the prior quarter.
  • Across five years, Research & Development topped out at $1.6 billion in Q4 2025 and bottomed at $794.3 million in Q2 2022.
  • Average Research & Development over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
  • Year-over-year, Research & Development surged 41.42% in 2022 and then grew 6.33% in 2025.
  • Regeneron Pharmaceuticals' Research & Development stood at $1.0 billion in 2022, then increased by 12.86% to $1.2 billion in 2023, then grew by 19.95% to $1.4 billion in 2024, then grew by 15.15% to $1.6 billion in 2025, then dropped by 5.08% to $1.5 billion in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.